Atossa Therapeutics (FRA:YAG2) 3-Year EBITDA Growth Rate : 42.20% (As of Mar. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Atossa Therapeutics 3-Year EBITDA Growth Rate?

Atossa Therapeutics's EBITDA per Share for the three months ended in Mar. 2024 was €-0.05.

During the past 3 years, the average EBITDA Per Share Growth Rate was 42.20% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 44.60% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 51.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Atossa Therapeutics was 67.40% per year. The lowest was -100.10% per year. And the median was 43.80% per year.

Competitive Comparison of Atossa Therapeutics's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Atossa Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Atossa Therapeutics's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atossa Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Atossa Therapeutics's 3-Year EBITDA Growth Rate falls into.

Atossa Therapeutics 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Atossa Therapeutics (FRA:YAG2) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Atossa Therapeutics 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Atossa Therapeutics's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Atossa Therapeutics (FRA:YAG2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Atossa Therapeutics Inc (FRA:YAG2) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

ATOS:USA ATOS:Mexico YAG2:Germany

Address

107 Spring Street, Seattle, WA, USA, 98104

Website

https://www.atossatherapeutics.com

Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company developing proprietary innovative medicines in areas of significant unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.

Atossa Therapeutics (FRA:YAG2) Headlines

No Headlines